295 related articles for article (PubMed ID: 26360382)
21. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
Nariani A; Williams B; Hariprasad SM
Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
[TBL] [Abstract][Full Text] [Related]
23. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
24. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
25. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Wolff B; Essex R; Young S; Hunt A; Gemmy Cheung CM; Arnold JJ; Barthelmes D; Creuzot-Garcher C; Gillies M;
Ophthalmol Retina; 2020 Sep; 4(9):861-870. PubMed ID: 32574830
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
28. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.
Yannuzzi NA; Patel SN; Bhavsar KV; Sugiguchi F; Freund KB
Am J Ophthalmol; 2014 Aug; 158(2):319-327.e2. PubMed ID: 24814167
[TBL] [Abstract][Full Text] [Related]
29. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
Park J; Lee M
BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595
[TBL] [Abstract][Full Text] [Related]
30. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
31. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.
Rothman AL; Beca FA; Tijerina JD; Schuman DM; Parrish RK; Vanner EA; Liu KC
Ophthalmol Glaucoma; 2024; 7(3):260-270. PubMed ID: 38266962
[TBL] [Abstract][Full Text] [Related]
32. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
[No Abstract] [Full Text] [Related]
33. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Changes in Retinal Nerve Fiber Layer Thickness after Intravitreal Anti-vascular Endothelial Growth Factor Therapy.
Jo YJ; Kim WJ; Shin IH; Kim JY
Korean J Ophthalmol; 2016 Apr; 30(2):114-20. PubMed ID: 27051259
[TBL] [Abstract][Full Text] [Related]
35. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
[TBL] [Abstract][Full Text] [Related]
37. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
38. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Jung JJ; Mrejen S; Freund KB
Retina; 2014 Mar; 34(3):519-24. PubMed ID: 24240557
[TBL] [Abstract][Full Text] [Related]
39. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis.
Nanji K; Sarohia GS; Kennedy K; Ceyhan T; McKechnie T; Phillips M; Devji T; Thabane L; Kaiser P; Sarraf D; Garg SJ; Sivaprasad S; Wykoff CC; Bakri SJ; Sheidow T; Bhandari M; Chaudhary V
Ophthalmology; 2022 May; 129(5):498-508. PubMed ID: 34871637
[TBL] [Abstract][Full Text] [Related]
40. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]